Onyx Pharmaceuticals Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Onyx Pharmaceuticals (Nasdaq: ONXX  ) soared as much as 10% today on news that it has settled a lawsuit with Bayer over its blockbuster cancer drug, Nexavar.

So what: Although it may seem like run-of-the-mill news since lawsuits are a dime a dozen in the biotech sector, this is actually quite significant for both parties. Onyx derives nearly all of its revenue from Nexavar, which it developed in collaboration with Bayer. The lawsuit derived from an accusation in 2009 that Bayer was attempting to circumvent its royalty payment obligations to Onyx on Nexavar and develop a drug very similar instead. Today's settlement clears the way for both companies to continue with their current collaboration. In addition, Bayer agreed to pay $160 million to Onyx for the rights to market Nexavar in Japan with the opportunity to earn another $15 million if certain milestones are met.

Now what: Without question, the Bayer lawsuit was a big gray cloud overhanging this stock. With the lawsuit now being settled, the attractiveness of Onyx just shot way up and so does the potential that the company will get bought out. The final, and perhaps most important, aspect of this settlement is that Onyx will retain its collaborative agreement with Bayer even if it's bought out. With a blood-cancer treatment called carfilzomib hopefully on its way to the FDA shortly and the company solidly profitable, I feel the future looks bright for Onyx shareholders.

Craving more input on Onyx Pharmaceuticals? Add it to your free and personalized watchlist to keep up on the latest news coming out of the company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong and on Twitter, where he goes by @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1568733, ~/Articles/ArticleHandler.aspx, 10/21/2016 6:31:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **